Gusti Ayu Agung Indah Cahyani
Universitas Udayana

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Micropropagation and integrated cannabidiol isolation from cannabis sativa for pharmaceutical development: systematic literature review Putu Sanitha Jayanti; I Made Agus Gelgel Wirasuta; Fainmarinat Selviani Inabuy; Luh Nyoman Ary Metta Andriani; Gusti Ayu Agung Indah Cahyani
JPPI (Jurnal Penelitian Pendidikan Indonesia) Vol. 12 No. 2 (2026): JPPI (Jurnal Penelitian Pendidikan Indonesia)
Publisher : Indonesian Institute for Counseling, Education and Theraphy (IICET)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.29210/020267239

Abstract

This systematic literature review evaluates cannabidiol (CBD) extraction, isolation, and purification from Cannabis sativa and the potential role of micropropagation in pharmaceutical development. Scopus, ScienceDirect, and Google Scholar were searched for English-language publications (2016–2026). Eligibility criteria followed PICOC, and reporting was guided by PRISMA 2020. Of 1,505 records identified, 157 duplicates were removed, 1,299 records were excluded during screening, two reports were unavailable, and 13 full-text articles were excluded, leaving 34 studies. Narrative synthesis examined micropropagation, extraction, and purification. Micropropagation showed potential for preserving clonal characteristics and cannabinoid profiles, although direct evidence linking micropropagated biomass to CBD isolation remained limited. Higher extraction yields did not consistently improve CBD concentration or purity. Twin-column recycling chromatography achieved 97.3% purity and 99.7% recovery, while integrated processing produced CBD exceeding 99% purity with 52% overall yield. All studies were rated high quality, despite methodological uncertainties. Heterogeneity prevented quantitative pooling, and incomplete documentation limited reproducibility. Standardized comparisons, analytical validation, and commercial-scale evaluation are needed to strengthen pharmaceutical-development recommendations.